erdafitinib,gemcitabine,cisplatin,carboplatin,enfortumab,pembrolizumab,cetrelimab,atezolizumab
seagen,merck,roche,janssen,astellas
['cisplatin', 'urothelial', 'imvigor130', 'cetrelimab', 'erdafitinib', 'enfortumab', 'norse', 'pembro', 'atezo', 'ev-103']
#asco2023 very informative discussion of treatment developments in metastatic #urothelialcarcinoma 1l cisplatin ineligible by including #norse: #erdafitinib cetrelimab / ev-103: enfortumab pembro / imvigor130: gc atezo siefker-radtke 
Prof. of Urology @LMU_Muenchen GU Oncology, Sports Medicine - Vice President R&D Bladder Cancer @JanssenGlobal 🚵‍♀️Passionate cyclist